Search

Displaying results 4831 - 4840 of 10000 in total
  1. Drug

    WIN 55212-2

    go.drugbank.com/drugs/DB13950
    Experimental

    It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling. … WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical

  2. Drug

    Ferumoxides

    go.drugbank.com/drugs/DB09508
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    KOS-2187

    go.drugbank.com/drugs/DB05946
    Experimental

    KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).

  4. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins.

  5. Drug

    Carbenoxolone

    go.drugbank.com/drugs/DB02329
    Experimental

    An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. … Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]

  6. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth.

  7. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

    Synonyms: Sn Mesoporphyrin
  8. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol.

  9. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

  10. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. … Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.